Multiple myeloma is a lifelong, relapsing cancer that requires frequent monitoring. Current blood tests may miss low levels of disease, while bone marrow testing is invasive, costly, and difficult to repeat—creating clinical blind spots for physicians, added burden for patients, and potentially delayed treatment decisions.

MyeloTrak® uses high-resolution mass spectrometry to identify each patient’s unique M-protein signature and track it over time through routine blood samples. Its highly sensitive, personalized approach can reveal disease changes earlier, support more timely clinical decisions, and reduce reliance on repeated bone marrow procedures.

Multiple myeloma is a lifelong, relapsing cancer that requires frequent monitoring. Current blood tests may miss low levels of disease, while bone marrow testing is invasive, costly, and difficult to repeat—creating clinical blind spots for physicians, added burden for patients, and potentially delayed treatment decisions.

MyeloTrak® uses high-resolution mass spectrometry to identify each patient’s unique M-protein signature and track it over time through routine blood samples. Its highly sensitive, personalized approach can reveal disease changes earlier, support more timely clinical decisions, and reduce reliance on repeated bone marrow procedures.

"The program challenged us to look beyond technical performance and define MyeloTrak’s clinical, patient, and economic value. The guidance from Mayo Clinic, ASU, and our mentors helped us sharpen our positioning and build a clearer path toward clinical adoption in the U.S."

Leo Huang
Co-founder and CEO, Marker X